Services
Products
Quality
About Us

CELL BIOLOGY - Cell Systems

Mononuclear Cells from Human Cord Blood (GBT hcbMNC)
Umbilical cord and placental blood is collected from deliveries at local hospitals. Mononuclear cells are separated through a hetastarch process or ficoll (histopaque) procedure. Cells are available fresh or cryopreserved. Fresh cells are shipped the same day they are processed for delivery the next morning. Cryopreserved cells are shipped on dry ice.

CD34+ Cells from Human Cord Blood (GBT hcbCD34+)
CD34+ hematopoietic progenitors are isolated from cord blood derived mononuclear cells using positive immunomagnetic selection. Hematopoietic progenitors express high levels of the cell surface glycoprotein CD34. As these cells mature and differentiate the levels of CD34 expression decrease. CD34+cells are capable of initiating long-term hematopoiesis both in vitro and in vivo. Cells are available fresh or cryopreserved.

Human Umbilical Cord Blood Derived Mesenchymal Stem Cells (GBT hcbMSC)
Mesenchymal stem cells are harvested and cultured from normal human umbilical cord blood. Cells are tested for purity by flow cytometry and for their ability to differentiate into osteogenic, chondrogenic and adipogenic lineages. Cells are positive for CD105, CD166, CD29, and CD44. Cells test negative for CD14, CD34 and CD45.

Human Dental Pulp Derived Mesenchymal Stem Cells (GBT hdpMSC)
Mesenchymal stem cells are harvested and cultured from extracted human third molars. Cells are tested for purity by flow cytometry and for their ability to differentiate into osteogenic, chondrogenic and adipogenic lineages. Cells are positive for CD105, CD166, CD29, and CD44. Cells test negative for CD14, CD34 and CD45.

Recent News

ISCT Annual Meeting in May
CellSeal™ Cryogenic Vials Announced
Indianapolis Firm Developing Technology to Ease Cancer Treatments

Upcoming Events

ISCT Annual Meeting in May

General BioTechnology LLC | 1102 Indiana Avenue (N. Stadium Drive) Indianapolis, Indiana 46202
"Advancing Cryopreservation in order to secure the future of Cellular Therapy & Research"